On May 16, 2019 Sutro Biopharma, Inc. (NASDAQ: STRO) reported that the company will present at the upcoming European Hematology Association (EHA) (Free EHA Whitepaper) Congress being held June 13-16, 2019, in Amsterdam (Press release, Sutro Biopharma, MAY 16, 2019, View Source [SID1234536431]). The abstract summarizes preliminary results from the first 14 patients enrolled in the company’s ongoing Phase 1 study of STRO-001, the first antibody-drug conjugate generated with Sutro’s novel cell-free protein synthesis technology, in patients with advanced B-cell malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:

Preliminary results of a Phase 1 dose escalation study of the first-in-class anti-CD74 antibody-drug conjugate (ADC), STRO-001, in patients with advanced B-cell malignancies.

Date: Saturday, June 15, 2019

Time: 5:30 p.m. – 7:00 p.m. CEST

Location: Poster Hall, RAI Convention Center, Amsterdam

Poster Session: Aggressive Non-Hodgkin Lymphoma – Clinical

Abstract Number: PS1071

The abstract was published today on the EHA (Free EHA Whitepaper) website. Following the conference, the poster will be accessible through the Clinical/Scientific Presentation and Publication Highlights page of the News section of the company’s website at www.sutrobio.com.